Subtopic Deep Dive
Neuroprotection in Ischemic Stroke
Research Guide
What is Neuroprotection in Ischemic Stroke?
Neuroprotection in ischemic stroke targets cellular cascades of excitotoxicity, inflammation, and apoptosis in the ischemic penumbra to extend salvageable brain tissue beyond revascularization windows.
This approach aims to preserve neurons in the peri-infarct zone during acute ischemia. Preclinical studies and phase II/III trials test agents like erythropoietin and hypothermia. Over 10 key papers from 2002-2020, including guidelines by Jauch et al. (2013, 7614 citations) and reviews by Jayaraj et al. (2019, 1331 citations), define the field.
Why It Matters
Neuroprotection addresses the 80-90% of ischemic strokes ineligible for thrombolysis or thrombectomy, potentially expanding treatment windows from 4.5 to 24 hours (Ginsberg, 2008). Erythropoietin showed safety and 1-month outcome improvement in acute stroke patients (Ehrenreich et al., 2002, 1028 citations). Targeting neuroinflammation could reduce disability in millions annually, as inflammation exacerbates blood-brain barrier damage (Yang et al., 2018; Jayaraj et al., 2019).
Key Research Challenges
Clinical Translation Failure
Preclinical neuroprotective agents fail phase III trials due to narrow therapeutic windows and heterogeneity in stroke models (Ginsberg, 2008). Over 200 compounds succeeded in animals but not humans. Timing and dosing remain inconsistent across trials (Kuriakose and Xiao, 2020).
Neuroinflammation Targeting
Inflammation drives secondary injury via microglia activation and BBB disruption, but anti-inflammatory drugs risk immunosuppression (Jayaraj et al., 2019, 1331 citations; Lakhan et al., 2009). Balancing neuroinflammation's dual protective/destructive roles complicates therapy (Iadecola et al., 2020).
Penumbra Heterogeneity
Ischemic penumbra varies by collateral flow and comorbidities, limiting uniform neuroprotection (Jauch et al., 2013). Patient stratification for trials remains unresolved (Yang et al., 2018).
Essential Papers
Guidelines for the Early Management of Patients With Acute Ischemic Stroke
Edward C. Jauch, Jeffrey L. Saver, Harold P. Adams et al. · 2013 · Stroke · 7.6K citations
Background and Purpose— The authors present an overview of the current evidence and management recommendations for evaluation and treatment of adults with acute ischemic stroke. The intended audien...
Guidelines for Management of Ischaemic Stroke and Transient Ischaemic Attack 2008
Peter A. Ringleb, Marie Germaine Bousser · 2008 · Cerebrovascular Diseases · 2.5K citations
This article represents the update of the European Stroke Initiative Recommendations for Stroke Management. These guidelines cover both ischaemic stroke and transient ischaemic attacks, which are n...
Guidelines for the Management of Spontaneous Intracerebral Hemorrhage
Lewis B. Morgenstern, J. Claude Hemphill, Craig S. Anderson et al. · 2010 · Stroke · 1.5K citations
Purpose— The aim of this guideline is to present current and comprehensive recommendations for the diagnosis and treatment of acute spontaneous intracerebral hemorrhage. Methods— A formal literatur...
Neuroinflammation: friend and foe for ischemic stroke
Richard L. Jayaraj, Sheikh Azimullah, Rami Beiram et al. · 2019 · Journal of Neuroinflammation · 1.3K citations
Pathophysiology and Treatment of Stroke: Present Status and Future Perspectives
Diji Kuriakose, Zhi‐Cheng Xiao · 2020 · International Journal of Molecular Sciences · 1.2K citations
Stroke is the second leading cause of death and a major contributor to disability worldwide. The prevalence of stroke is highest in developing countries, with ischemic stroke being the most common ...
Inflammatory mechanisms in ischemic stroke: therapeutic approaches
Shaheen E Lakhan, Annette L. Kirchgessner, Magdalena Hofer · 2009 · Journal of Translational Medicine · 1.1K citations
Acute ischemic stroke is the third leading cause of death in industrialized countries and the most frequent cause of permanent disability in adults worldwide. Despite advances in the understanding ...
Erythropoietin Therapy for Acute Stroke Is Both Safe and Beneficial
Hannelore Ehrenreich, Martin Hasselblatt, Christoph Dembowski et al. · 2002 · Molecular Medicine · 1.0K citations
Intravenous high-dose rhEPO is well tolerated in acute ischemic stroke and associated with an improvement in clinical outcome at 1 month. A larger scale clinical trial is warranted.
Reading Guide
Foundational Papers
Start with Jauch et al. (2013, 7614 citations) for management guidelines integrating neuroprotection status; Ehrenreich et al. (2002, 1028 citations) for first EPO trial evidence; Lakhan et al. (2009) for inflammation mechanisms.
Recent Advances
Study Jayaraj et al. (2019, 1331 citations) for neuroinflammation updates; Iadecola et al. (2020, 759 citations) for immune modulation potential; Kuriakose and Xiao (2020, 1221 citations) for pathophysiology advances.
Core Methods
Core techniques: rhEPO infusion (Ehrenreich et al., 2002); microglia inhibitors (Jayaraj et al., 2019); preclinical penumbra imaging and apoptosis assays (Ginsberg, 2008).
How PapersFlow Helps You Research Neuroprotection in Ischemic Stroke
Discover & Search
PapersFlow's Research Agent uses searchPapers and exaSearch to find 250M+ papers on neuroprotection, revealing citationGraph hubs like Jauch et al. (2013, 7614 citations) linking to EPO trials. findSimilarPapers expands from Jayaraj et al. (2019) to 50+ inflammation studies.
Analyze & Verify
Analysis Agent applies readPaperContent to extract EPO dosing from Ehrenreich et al. (2002), then verifyResponse with CoVe chain-of-verification against guidelines. runPythonAnalysis performs meta-analysis on GRADE-graded trial outcomes from Lakhan et al. (2009) and Iadecola et al. (2020), plotting effect sizes with pandas/matplotlib.
Synthesize & Write
Synthesis Agent detects gaps in EPO phase III follow-ups post-Ehrenreich et al. (2002), flagging contradictions in inflammation roles (Jayaraj et al., 2019 vs. Iadecola et al., 2020). Writing Agent uses latexEditText, latexSyncCitations for guideline-integrated reviews, and latexCompile for publication-ready manuscripts with exportMermaid for penumbra cascade diagrams.
Use Cases
"Extract clinical outcomes from erythropoietin stroke trials."
Research Agent → searchPapers('erythropoietin ischemic stroke') → Analysis Agent → readPaperContent(Ehrenreich 2002) → runPythonAnalysis(pandas meta-analysis of outcomes) → researcher gets GRADE-scored summary table with p-values.
"Draft review on neuroprotection trial failures with citations."
Synthesis Agent → gap detection(inflammation trials) → Writing Agent → latexEditText('review text') → latexSyncCitations(Jauch 2013, Ginsberg 2008) → latexCompile → researcher gets PDF with formatted references and figures.
"Find code for ischemic penumbra modeling."
Research Agent → searchPapers('penumbra simulation stroke') → Code Discovery → paperExtractUrls → paperFindGithubRepo → githubRepoInspect → researcher gets runnable Python scripts for BBB inflammation models.
Automated Workflows
Deep Research workflow conducts systematic review of 50+ neuroprotection papers, chaining searchPapers → citationGraph → GRADE grading for EPO efficacy (Ehrenreich et al., 2002). DeepScan applies 7-step analysis with CoVe checkpoints to verify inflammation mechanisms across Jayaraj et al. (2019) and Yang et al. (2018). Theorizer generates hypotheses on combined hypothermia-EPO protocols from guideline gaps (Jauch et al., 2013).
Frequently Asked Questions
What defines neuroprotection in ischemic stroke?
Neuroprotection targets excitotoxicity, inflammation, and apoptosis in the penumbra to salvage tissue (Ginsberg, 2008). It extends beyond recanalization for non-revascularizable cases.
What are key methods in neuroprotection research?
Methods include pharmacological agents like rhEPO (Ehrenreich et al., 2002), anti-inflammatories (Lakhan et al., 2009), and hypothermia. Trials emphasize timing within 6-24 hours post-stroke.
What are seminal papers?
Jauch et al. (2013, 7614 citations) provide AHA guidelines; Ehrenreich et al. (2002, 1028 citations) validate EPO safety. Jayaraj et al. (2019, 1331 citations) review neuroinflammation.
What open problems exist?
Translating preclinical success to phase III (Ginsberg, 2008); resolving inflammation's dual roles (Iadecola et al., 2020); stratifying penumbra patients (Kuriakose and Xiao, 2020).
Research Acute Ischemic Stroke Management with AI
PapersFlow provides specialized AI tools for Medicine researchers. Here are the most relevant for this topic:
Systematic Review
AI-powered evidence synthesis with documented search strategies
AI Literature Review
Automate paper discovery and synthesis across 474M+ papers
Find Disagreement
Discover conflicting findings and counter-evidence
Paper Summarizer
Get structured summaries of any paper in seconds
See how researchers in Health & Medicine use PapersFlow
Field-specific workflows, example queries, and use cases.
Start Researching Neuroprotection in Ischemic Stroke with AI
Search 474M+ papers, run AI-powered literature reviews, and write with integrated citations — all in one workspace.
See how PapersFlow works for Medicine researchers
Part of the Acute Ischemic Stroke Management Research Guide